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nomic issues. Advances in biotechnology will likely affect the well-
being of people throughout the world for many years to come. While
we can only speculate on the specific form of advances that will be made,
we can address many of the economic questions raised by developments
in the life sciences. What potential economic benefits does biotechnology
offer? How is the emergence of the biotech industry similar to the infancy
of now-established industries? Where do biotech firms locate? How will
biotech research be financed and what are the funding hurdles? What
legal and regulatory issues will confront the industry?
To  address these and other important questions surrounding the
development of biotechnology, the Federal Reserve Bank of Dallas hosted
the conference “Science and Cents: Exploring the Economics of Biotech-
nology” on April 19, 2002. The conference brought together distinguished
experts who spoke about economic and scientific issues surrounding bio-
technology.
This article highlights the main points and summarizes the presen-
tations made at the conference. Conference presentations can be viewed
at www.dallasfed.org/htm/dallas/events/archive/02biotech.html.
The first session provided an economic perspective on the biotech
revolution, with one speaker discussing how this revolution compares with
other periods of major technological change and another quantifying some
of the benefits from the pharmaceutical sector, the most established
biotech-related industry. Another session examined the difficulties biotech
firms encounter in capturing the economic value from expensive and
lengthy research. Reflecting the changing nature of research in the life 
sciences, two speakers discussed how and why two important sources of
financing—venture capital and public funding—have evolved in recent
decades. Two presentations described the nature of advances in the life
sciences, with one providing an overview of basic biotech research and
the other focusing on likely areas of future discoveries. The final session
focused on the factors driving the location of biotech research and what
regions can do to foster such activity.Throughout this overview, we use the
term biotechnology in a broad sense, as “the application of the principles
of engineering and technology to the life sciences” (American Heritage
Dictionary).The technical terms used in this article are defined in the glos-
sary. We conclude with a discussion of the broad economic implications of
biotechnology.
AN ECONOMIC PERSPECTIVE ON THE BIOTECH REVOLUTION
In providing an economic perspective on whether biotech advances
will kindle a new industrial revolution, the opening speaker, Professor
Michael Darby of the University of California at Los Angeles (UCLA), drew
on his paper to be published in 2003 in Economic Inquiry (Darby and
Zucker, forthcoming). He emphasized that biotech research appears to
represent a major, metamorphic revolution in which new industries are cre-
ated, rather than incremental progress that perfects existing products. As
with earlier metamorphic revolutions, a lack of data and history hampers
our ability to gauge biotech’s importance.
Another characteristic of metamorphic revolutions is that many new
firms enter an emerging industry that has few or no incumbents, but just a
fraction of these new firms succeed and thrive.With the biotech sector still
in its formative stage, the number of biotech firms will probably rise before
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Tdeclining during the shake-out phase that often occurs in the development
of an industry. Nevertheless, as Darby stressed, many of the economic
benefits to society accrue during the consolidation and maturation stages
of an industry’s life cycle.
Darby also noted that biotech research is hard to imitate and has a
natural excludability, in that innovators have a profound advantage over
imitators in creating successful applications from the research. In particu-
lar, success in biotech is highly correlated with links to star scientists at
universities, and these links are empirically the most important factors
affecting the probability of success. For this reason, Darby stressed that
drawing top scientific talent and expanding university research are critical
to increasing biotech activity in areas like Texas.
Columbia University Professor Frank Lichtenberg reviewed some of
the limited evidence on biotech’s promise from studies of the economic
benefits of drugs, arguably the most established biotech-related industry
(Lichtenberg 2002). These benefits include lower overall medical costs,
higher productivity, and increased longevity. Recently, much attention has
been paid to rising drug costs. But, as French economist Frédéric Bastiat
emphasized long ago, economists should consider what is unseen, not
just what is seen.
For example, with respect to medical costs, what is seen—the $18
increase in the cost of new drugs per person—is more than offset by what
is unseen—a $129 estimated decline in net, nondrug medical costs.
1
These savings stem mainly from more effective new drugs eliminating or
shortening hospital stays.
In addition to these cost savings, there are gains from boosting
worker productivity. In particular, Lichtenberg’s econometric studies esti-
mate that for every $34 employers and employees spend on prescriptions,
the cost of sick days falls by roughly $40. Additional gains of $112 arise
because pharmaceuticals improve the on-the-job performance of those
already working and enable the disabled to enter the workforce. Together,
these estimates imply that $34 spent on prescriptions boosts output by
roughly $152.
Another major benefit from pharmaceuticals is increased life ex-
pectancy. For example, between 1979 and 1997, the United States spent
an average of $13 billion a year to develop new drugs that collectively
boosted longevity by nearly five months, according to research. As Lichten-
berg noted, by some economic yardsticks, this increase in life expectancy
is worth about $120 billion a year. Other data linking pharmaceutical 
advances to longevity include time-series evidence of a positive correla-
tion between new drug approvals and life expectancy and between HIV
drug approvals and reductions in HIV-related deaths. Lichtenberg cited the
latter as evidence for the positive impact of the Orphan Drug Act of 1983,
which reduced the hurdles for developing treatments or cures for certain
classes of diseases.
Of course, these findings about the benefits of pharmaceuticals are
based on past experience, and there is no guarantee that future advances
will pay off as handsomely. Nevertheless, the track record for new phar-
maceuticals is impressive and should be considered when evaluating 
policy proposals that affect the incentives for innovation. This caution also
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applies to other biotech-related industries, especially in light of the key role
that highly risky research plays in biotech advances, as illustrated by other
conference speakers.
LEGAL AND REGULATORY ISSUES
The speakers in this session offered perspective on the legal and
regulatory issues surrounding biotechnology. Duke University Professor
Henry Grabowski emphasized that two of the biggest hurdles for drug re-
search are high risk and high costs (Grabowski 2002). Professor Rebecca
Eisenberg of the University of Michigan stressed the importance of patent
strategies to capture the returns to R&D in biotech (Eisenberg 2002).
The High-Risk and High-Cost Hurdles to R&D
Grabowski noted that only 22 percent of drugs that enter clinical 
trials eventually receive FDA approval. Furthermore, even among approved
drugs there are few winners, as evidenced by three facts. First, only one-
third of approved pharmaceuticals cover out-of-pocket expenses, which
are not adjusted for risk or time. Second, the 20 percent of new drugs with
the highest revenues as a group outsell the remaining 80 percent com-
bined.Third, earnings at large pharmaceutical companies are mainly from
a few drugs, in some cases just one or two.
Another important hurdle for drug research is that R&D costs are
high and are rising quickly. Grabowski estimated that it costs about $400
million, on average, in out-of-pocket expenses to develop a new drug. In
addition, along with the high risks, there is a lengthy ten- to twelve-year
gestation period to develop a drug. Adjusting out-of-pocket costs for risk
and time, Grabowski and his fellow researchers estimate that it costs
roughly $800 million to develop a new drug.
He also noted that R&D costs have generally increased more rapidly
than inflation. Older data show that clinical costs rose 12 percent faster
than inflation during the 1980s, after exceeding inflation by 6 percent per
year in the 1970s. Despite a slowing of nonclinical cost increases, overall
R&D cost increases outpaced overall inflation by roughly 7.5 percentage
points per year in the 1980s, after outpacing inflation by 7 percent per year
in the 1970s. Incomplete data indicate that this pattern likely continued in
the 1990s. Especially noteworthy is the doubling of the length of clinical tri-
als from 33 months in the 1980s to 67 months today.
In light of the high and rising costs of biotech R&D, inventors need to
capture enough of the economic returns to make their investment worth-
while. In general, biotech firms defend their intellectual property through
formal patents and an evolving set of legal strategies.
Devising appropriate patent protections is a balancing act. Because
R&D costs and risks are high, patents need to be long enough for firms to
recoup their risk-adjusted R&D costs without unduly dissuading patent
holders or their potential competitors from conducting more research.
Grabowski pointed out that patents provide outsiders with information
about new discoveries that, in turn, spurs more research. As Grabowski
emphasized, patents are the most important factor affecting R&D deci-
sions, according to surveys of biotech firms.
The economics of developing new drugs differs from that of develop-
ing generic versions of existing drugs. First, the out-of-pocket costs of
developing a generic are only $1 million to $2 million, far below the $400
million for developing a new drug. Second, the clinical success rate forgenerics is 90 to 100 percent, four to five times that of new drugs. Finally,
it takes only one to two years to develop a generic versus ten to twelve
years for a new drug.
Capturing the Returns to Research
Another impediment to capturing the returns to biotech R&D is that
earlier established patent practices may not be suitable for the fast-changing
biotech landscape because it takes a while for the law to catch up with sci-
ence. As Eisenberg stressed, the rapid development of biotech science
has led to a rapid evolution in patent strategies. Today, the value of an
innovation is not in the direct production of therapeutic or diagnostic prod-
ucts but in the use of that invention in research and product development.
Moreover, it is not obvious how to use patents to capture the value of these
research technologies. For this reason, many innovators pursue reach-
through strategies to claim a share of the value of future products. These
strategies entail innovators and their start-up firms (upstream firms) reach-
ing into future revenues from the end products that are developed using
their inventions. Not surprisingly, the established pharmaceutical and
biotech firms (downstream firms) strongly oppose these strategies.
Eisenberg listed three main strategies for capturing the value of
research in biotech: reach-through licensing, reach-through remedy, and
reach-through claiming. Reach-through licensing refers to a patent holder
restricting access to a patented research-enabling technology to users
that agree, as a term of the license, to share a portion of the revenue or
profits from future products.
A reach-through remedy is an ex post damage award for infringe-
ment that is measured as a reach-through royalty on sales of products
developed through unlicensed use of a research tool. Under this strategy,
researchers who use an innovation without permission are only liable for
reach-through royalties if their research yields a successful product.
Reach-through claiming is an approach that depends more on
patents. In this case, patents are issued that are broad enough to cover
future discoveries enabled by prior inventions. If the patent covers future
products, there is no need to get the user to agree to pay royalties for
future products. The primary obstacle to reach-through claiming arises
from the disclosure requirements of patent law. The patent-seeker must
supply information about the structure of products covered by the claim
and not just their function.In addition, a successful patent application must
demonstrate that the invention is necessary to the successful development
of the products in question. Providing such a description is sometimes
impossible because the innovator does not know beforehand what partic-
ular molecular structures will be developed using the patented invention.
Eisenberg discussed the pros and cons of reach-through strategies.
One argument against such strategies is that they overcompensate those
who rest on their laurels at the expense of those who carry the research for-
ward. A second objection is that such strategies give innovators too much
control over future research, which could inhibit innovation. Another argu-
ment is that although there have been many path-breaking discoveries in
biotech, government funding has paid for them, through such agencies as
the National Institutes of Health (NIH). Hence, reach-through strategies are
not needed to motivate and reward this basic research.
The arguments in favor of reach-through strategies contrast sharply
with this last objection. One position favoring reach-through practices 
is that they enable researchers to capture the value that their discov-
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is riskier and less likely to have high stand-alone value than down-
stream research, which is more closely related to marketable products.
In the past three decades the pharmaceutical business has been very
profitable, while other biotech-related industries have mostly been un-
profitable. Proponents of reach-through strategies maintain that this pat-
tern occurs because biotech innovators cannot recapture the value that
their inventions have contributed to the pharmaceutical industry.
Eisenberg argued that reach-through strategies help with the valua-
tion and financing of biotech research and tools. In the absence of reach-
through agreements, firms using innovations would pay up-front fees 
for using inventions. Such pay-as-you-go practices would suit pharmaceu-
tical firms well because they have plenty of cash and would rather pay a
relatively small amount up front. However, reach-through agreements
allow upstream and downstream biotech firms and universities to form
joint ventures, sharing risks without draining cash at the research stage.
Eisenberg concluded by observing that patent law has a tradition of
limiting protection to actual accomplishments and future variations that
arise from work that is routine and predictable. She believes this is a sen-
sible limitation that guides patent examiners away from acceding to patent
claims that would unreasonably cover future research. Eisenberg believes
there are good reasons for permitting prior innovators to capture a fair
share of the value their discoveries contribute to subsequent downstream
innovation. Nevertheless, she is generally more comfortable with strate-
gies in which licenses are negotiated in the market than with strategies
negotiated in the course of patent prosecution.
FUNDING BIOTECH RESEARCH
Funding expensive research that has highly risky returns is another
hurdle for biotech. Aside from pharmaceutical research, which is often
done by established companies, much biotech research is conducted by
new firms partly funded by venture capitalists and other private equity
investors. Much of their applied research is based on basic or generic
research that is either publicly funded or conducted at publicly funded uni-
versities and other institutions. For some perspective on the relative impor-
tance of funding sources, note that in 1999, NIH outlays (including non-
R&D expenses) amounted to $13.8 billion, while private R&D outlays on
health research totaled $11 billion. The latter figure excludes research at
universities but includes expenditures by large pharmaceutical firms and
much of the $2.2 billion in venture capital invested that year. Given that
future biotech research is likely to branch out beyond old-style pharma-
ceutical R&D, the session on funding biotech research focused on the
roles played by venture capital and the public sector.
Venture Capital: Its Role and Prospects
Timothy Howe, founding partner of a venture capital firm, empha-
sized several points about the role of venture capitalists (Howe 2002).
First, biotech venture capital firms combine managerial with scientific tal-
ent in picking, funding, advising, and even managing biotech start-ups. By
performing these roles, venture firms enable scientists in start-ups to focus
on inventing. A second point is that most venture firms directly invest in
young companies, without intermediaries. Third, the distribution of returns
is highly skewed, with few big winners.
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incentive to diversify their investments across different solutions to medical
problems, which can be found not only in biotechnology but also in med-
ical devices and service firms. Finally, the rising share of GDP devoted to
health and the related aging of the baby boom generation offers big incen-
tives for venture capital firms to enter the medical arena. Howe stressed
that the population age 55 and older is projected to grow at a pace five
times that of younger cohorts. This is important because the older group
spends much more on health; for example, people 55 and over spend an
average of three times more days per year in the hospital than do younger
people.
Howe discussed two general opportunities for venture capital. The
first concerns a shift in the type of science funded. Venture firms focused
on funding conventional drug development in the 1980s and genomics in
the 1990s. Looking ahead, venture firms are likely to fund projects in pro-
teomics, the study of how human genes produce proteins that act upon 
the body. As Howe stressed, the human genome project has identified 
over 35,000 genes that have a role in producing proteins, but current 
drugs work on only 400 proteins. Although much more complicated than
genomics, proteomics offers the benefits of customizing drugs. Proteomic
advances would enable physicians to tailor treatments to a patient’s
genetic makeup, appropriately affecting the body’s output of proteins and
thereby reducing toxic side effects.
Howe sees the other big opportunity in the maturation of the oldest,
most established biotech-related industry, pharmaceuticals, from a verti-
cally integrated industry to a horizontally organized one. Building upon
insights from Andrew Grove’s (1996) book, Only the Paranoid Survive,
Howe likened the drug industry to the computer industry of twenty years
ago, which was dominated by big, vertically integrated firms like IBM, DEC,
Sperry-Univac, and Wang.Two decades ago, each of those firms did it all—
manufacturing chips and computers, designing application systems and
software, and selling and distributing products. Since then, as Grove points
out, the computer industry has been transformed into a horizontally inte-
grated industry with a few big players dominating each particular segment.
For example, leaders have arisen within particular segments of the com-
puter industry, including Intel in chips, Dell and the newly merged Hewlett-
Packard and Compaq in personal computers, and Microsoft in operating
systems and software. Similarly, Howe sees the pharmaceutical industry
becoming dominated by a few major players in distinct horizontal segments,
such as research and target discovery, clinical testing, and distribution.
The Public-Sector Role in Funding Biotech Research
Another important source of funding for biotech research is govern-
ment.Wake Forest University Professor Michael Lawlor emphasized that the
benefits resulting from certain types of research warrant some form of public
subsidy (Lawlor 2002).The returns to R&D have historically exceeded those
on other investments. At the macroeconomic level, U.S. growth has arisen
more from innovation than directly from growth in the capital stock or labor
force. But if the returns were so large, why hasn’t there been more invest-
ment, which would drive the returns down to normal? One reason is that
there are high-risk premiums on biotechnology investments because there
are few winners. Another is that the economic value generated by inventors’
discoveries spills over to others. Indeed, most microeconomic studies find
that inventors recoup only a part of the economic value of their research.
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investment, along with the drawbacks of each. An industrial policy, which
invests directly in the research and production of goods, poses challenges
associated with state enterprises operating in a dynamic area. Tax credits
sound appealing, but it is hard to prevent firms from reclassifying other
expenses as R&D, thereby diluting the effectiveness of a tax cut.The final
option is direct funding of R&D, but this runs the risk of project selection
being politicized or not accountable enough.
According to Lawlor, a complex, direct-funding approach has evolved
in this country, helping make the United States the world leader in biotech
research. He noted that the public role in R&D surged during World War II
when the federal government boosted its direct funding of research, with
projects ranging from developing the atomic bomb to perfecting the mass
production of penicillin. After the war, federal funding for health research
focused on basic research, driven by curiosity and Cold War concern.This
effort was linked to security and politics and was less directed at applied
research having commercial applications.
During the early years of the Cold War, NIH funding expanded greatly.
NIH is a hybrid institution whose social mission is set and funded from the
top but whose operations are largely decentralized. Congress sets NIH’s
budget, but scientists choose which research projects to fund in a careful
peer-review process.This allows for accountability, flexibility, and competition.
Lawlor stressed that in recent decades, public funding of R&D has
evolved in response to the increased complexity of research, which is
more interdisciplinary and which has blurred the lines between basic and
applied research. In particular, new technologies are now often applied in
many fields and are therefore referred to as generic technologies.
Recognizing these trends and seeking to encourage the transfer of
federally funded research to the private sector, Congress passed legislation
in the mid-1980s that created cooperative research and development agree-
ments (CRADAs). These CRADAs allow federally funded laboratories to
establish profitable research links with commercial firms that draw on lab
research findings. In addition, in 1996 the Department of Commerce insti-
tuted the advanced technology program, which directly funds research into
developing new generic processes for high-tech industries. This program
has been instrumental in speeding up and reducing the financial risk of
research in stem cells, regenerating human tissue, and treating diabetes.
THE INTERDISCIPLINARY NATURE OF BIOTECH RESEARCH
Given the importance of scientific breakthroughs to the development
of biotech industries, two of the conference presentations focused on 
the complex, interdisciplinary nature of biotechnology research. Rice Uni-
versity President Malcolm Gillis focused on the critical roles nanotech-
nology and bioinformatics will likely play in advances in biotech (Gillis
2002). Tom Caskey, head of a biotech venture capital fund, stressed how
innovations from several areas of science are being used in the new field
of proteomics (Caskey 2002).
The Future of New Technologies Related to Biotechnology
As Gillis noted, development of the biotech industry will fuel growth 
in dozens of other industries and thereby foster overall economic growth.
He predicted that biotech will grow ever faster as applications extend beyond
pharmaceuticals and agriculture to nutrition, energy production, tissue engi-
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results from a single invention or a single set of technologies. Instead, rapid
growth is generally caused by the interplay of a collection of discoveries 
in different fields over a long period. Biotech progress is propelled by a 
synthesis of new technologies, not only from the biosciences but also from
other sciences, such as information technology and nanotechnology.
In discussing biotech and infotech, Gillis noted that mathematical,
statistical, and computer methods are indispensable to analyzing biological,
biochemical, and biophysical data. The techniques developed in this field
of bioinformatics weave together biology and information science. Compu-
tational physiology is one of several bioinformatics subfields moving ahead
at high speed. One example of a product in computational physiology is
the virtual heart, which required the translation of thousands of mathe-
matical equations and data points into a computer simulation of a heart.
Another subfield is computational cancer research, which deals with
an overwhelming number of possible combinations and permutations of
cancer-causing mutations, a problem bioinformatics is well suited to handle.
Yet another subfield is pharmacogenomics, which combines computational
sciences with biochemistry and pharmacology and offers the potential for
customizing drugs to the genetic makeup of individuals and developing
new insights into disease prevention.
Gillis also described the growing research in the interface between
biotechnology and nanotechnology. Nanotechnology is the application of
findings of nanoscale science, which deals with objects as small as a
nanometer (one-billionth of a meter).To provide perspective, Gillis noted that
a typical thumb is 30 million nanometers wide.
Biomedical applications of nanotech were given a large boost when
Rice University researchers discovered two geodesic-shaped and very
stable nanoparticles: carbon 60 (also called Buckyball after Buckminster
Fuller, an inventor, philosopher, and architect who experimented with geo-
desic shapes) and carbon 70 (another so-called Fullerene). The surfaces
of the nanoparticles are extremely suitable for attaching therapeutic com-
pounds. The particles can then deliver the drugs to specifically targeted
sites in the body. For example, the particle’s shape facilitates easy binding
with HIV-infected cells.
Another example of a nanoparticle is a gold nanoshell (a gold surface
adhered to a silica core). Rice University and M.D. Anderson Hospital are
working together on the diagnosis and treatment of cancer using gold
nanoshells. Because of their small size, nanoshells pass easily through the
circulatory system, which can deliver them to individual tumors. Physicians
can then direct infrared light onto the tumors, which heats the nanoshells
as high as 55 degrees C (131 degrees F), enough to destroy the cancer
cells but leave healthy cells intact.
Gillis also spoke of developments in the design and use of nano-
materials for biomedical engineering. The most notable of these is tissue
engineering, which focuses on the development of biological substitutes to
restore, maintain, or improve tissue function. Examples include bone and
organ replacement and the development of blood substitutes.These inno-
vations require several types of new technology. In particular, nanotech-
nology is used to create the tissue analogs to grow skin, bone, and organs.
Engineering and computational skills are needed to construct the mathe-
matical models and create images used in the bioscientists’ work.
Gillis forecasted that biotech would be the principal arena for an
ongoing, far-reaching synthesis in science and engineering. He noted that
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striking impact on health maintenance, diagnosis, and treatment. He pre-
dicted that biotech will provide an array of products and services to fuel
sharp increases in living standards in the twenty-first century.
The Convergence of New Technologies in Biotechnology Research
Caskey discussed the convergence of new technologies that enable
a new industrial approach to health products. He noted that many different
technologies in chemistry and biology are being combined to develop new
therapeutics. For example, recombinant DNA technology and genome
sequencing have helped researchers understand the structure of the HIV
virus and have aided work on developing vaccines and treatments for HIV.
More broadly, advances in recombinant DNA technology, the study of cell
growth, proteomics, and bioinformatics contribute to the development of
proteins that can be used to treat or prevent disease. Drawing on huge
accumulated databases about protein structure and behavior, scientists
can now predict how proteins will function. Such research has led to the
development of replacement proteins, such as insulin and interferon, and
of inhibitory proteins, such as monoclonal antibodies.The study of human
genetics and the discovery of disease–gene associations have also bene-
fited research into drugs for Alzheimer’s disease.
Caskey also briefly discussed the financial drivers of the biotech indus-
try, pointing out that the NIH and large pharmaceutical firms are the main
source of funds, with a small amount coming from venture capital. He then
spoke of some developments in Texas and shared his ideas about what is
needed to foster biotech in the state. These include increasing the number
of new firms, improving the recruitment of pharmaceutical and large biotech
firms to the region, and enabling in-state and out-of-state firms to consoli-
date. Achieving these goals requires improving business plans and man-
agement, recruiting more biotech talent, bolstering venture capital funding,
and improving state and regional incentives, Caskey concluded.
THE LOCAL DETERMINANTS OF BIOTECH
The last session of the conference concentrated on the local deter-
minants of biotechnology. Dennis Stone, vice president for technology
development at the University of Texas Southwestern Medical Center in
Dallas (UTSW), focused on biotech activity in the Dallas/Fort Worth metro
area. UCLA Professor Lynne Zucker discussed what factors have affected
the location of biotech firms across the United States.
The University’s Role in Biotech Development in D/FW
Stone emphasized the role of the university in the biotech industry,
focusing on developments in the Dallas/Fort Worth metro area. Unlike the
information technology industries, biotech depends on the university as a
technology source. Stone illustrated the scope of the University of Texas’
biotech presence, using life science research expenditures and patent data
(Stone 2002). In 2000, Texas was third in the nation in life science research
expenditures, with an outlay of $1.3 billion, including $750 million in expen-
ditures at the University of Texas. Moreover, the University of Texas system
was fifth in the nation in the number of patents generated during 2001.
Stone then discussed the Biotechnology Initiative, a joint effort of 
the city of Dallas, the Dallas Plan, UTSW, and STARTech Early Ventures,
a business accelerator, to foster the industry’s growth in Dallas.The initia-
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for Dallas-based biotech companies and to recruit biotech and pharma-
ceutical companies to Dallas. UTSW’s role is to be the source of platform
technologies, staff, and expertise and to serve as a resource for materials
and ongoing developmental and clinical work.
To  better support commercialization, UTSW created the Office of
Technology Development (OTD) in 1998. Since its formation, the OTD has
launched three start-ups, doubled its staff and more than quadrupled its
licensing revenues.The OTD was also recognized by the Texas Legislature
in 2001 as a leading technology development center.
Stone noted that Dallas has very few biotech companies because of
barriers to entry facing start-ups. In his opinion, the main barriers include
the lack of biotech entrepreneurs, the lack of local venture capitalists, the
academic culture of local faculty, and the fact that UTSW cannot form com-
panies. By default, the OTD’s main option is to license the technology to
existing entities. UTSW has also joined forces with STARTech to overcome
some of these barriers. STARTech helps with company formation by iden-
tifying management and finding the venture capitalists and seed capital
necessary to start a company.
The OTD’s criteria for backing a start-up are quite stringent. First, the
firm must have broad platforms that enable multiple discoveries or product
pathways. Second, the foreseeable market size for the line of products
must exceed $1 billion per year.Third, the time to market must be less than
five years. Finally, the inventor must be a suitable partner for the company.
Some of the successful start-up companies in the pipeline are Origami,
Chia, Signal Biotechnology, Light Biology, and Eliance (since bought by
Microgenics).
In closing, Stone stressed that fostering the growth of seed capital,
venture capital, and biotech space will enable the biotech industry to flour-
ish in Dallas. In addition, Stone saw a need to increase the flexibility of
firms to operate with a public institution such as UTSW and to bolster
cooperation among North Dallas stakeholders.
Commercializing Knowledge: University Science and Firm Performance
The last speaker of the conference, Zucker began with a glimpse of
Texas’ science base. Using several gauges, she compared how Texas
stacks up against other high-tech states. She showed that except for the
quality of patents, Texas was near the national average and 20 percent
below the high-tech-state average for a variety of measures of scientific
prowess.
Zucker stressed that the biotechnology industry has few big winners
and many losers, as only 10 percent of biotech start-ups grew into rea-
sonably large firms.To gauge the strength of local biotech activity, Zucker,
in research done with Darby and Armstrong (Zucker, Darby, and Arm-
strong 2002), included not only technological indicators, such as patents,
products marketed or in development, and firm size, but also financial indi-
cators covering financing (initial public offerings, venture capital, mergers,
and acquisitions) and income (revenues, sales, licensing, and profits).The
science base of a state was very important in determining the success of
biotech firms. Using data through the early 1990s, she showed that the
most successful firms were clustered in the Northeast and on the West
Coast and that Texas was not on the map for any of these indicators.
However, another speaker, Tom Caskey, stressed that the state’s ranking
may not be as low today, pointing out that Zucker’s data were roughly a
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Zucker’s research shows that basic university science is integral to
successful commercialization of scientific discoveries. Intellectual capital
flourishes around the best universities, but outstanding scientists play a
role over and above the presence of the universities and government
research funding. Firms working with star scientists are much more likely
to be successful, controlling for other factors. Star scientists who collabo-
rate with outside firms provide the intellectual human capital that defines
the firm’s core technology and largely determines the company’s success.
For example, the Zucker, Darby, and Armstrong (2002) study finds that five
articles coauthored by academic stars and the firm’s scientists are corre-
lated, on average, with about five more products in development, 3.5 more
products on the market, and 860 more employees. Their research also
shows that local venture capital is very important to the industry’s growth,
increasing R&D productivity and fueling firms’ expansion.
Zucker concluded by noting that Texas’ biotech success would be
driven by the number and quality of top research university bioscientists,
especially those with ties to firms, and stressed the need for more invest-
ment in Texas’ scientific base.
THE BROAD ECONOMIC IMPLICATIONS OF BIOTECHNOLOGY
Several broad implications arise from the conference presentations.
One is that if past technological revolutions are any guide, more research
is needed to develop gauges of biotech activity. Also, the benefits of
biotech advances are likely to be felt long after the inevitable shakeout
periods that will cull the ranks of biotech firms. In addition, at a time when
health care premiums are growing rapidly and drug cost increases are 
getting a lot of press, we should remember that the benefits of new drugs
have historically outweighed their higher costs. That’s why Lichtenberg
emphasizes that restricting drug benefits or drug prices to hold down med-
ical costs could backfire.
Another broad implication is that while policymakers should spur
basic and generic research, they should ensure that incentives are appro-
priate for markets to perform efficiently. With respect to funding, it is en-
couraging that NIH’s 2003 budget is twice what it was for 1998. But inter-
ventions in the form of price controls or forcing biotech firms to relinquish
property rights could reduce the incentives for innovation.The risky nature
of biotech research was a theme common to several conference speakers,
including Darby, Grabowski, Howe, and Zucker. Given the high cost and
risks of biotech research, emerging industries need a few big winners to
justify investing in many new ideas.And as Eisenberg stressed, patent and
royalty laws need to catch up to the technology so the markets can per-
form better.
Another set of implications concerns the interdisciplinary nature of
biotech research, which encompasses a broad scientific base and which
may greatly affect other areas and industries. Current biotech science
draws on advances in chemistry, biology, computational methods, and med-
icine to develop new therapeutics.The knowledge and expertise from these
different areas is being utilized in the hopes of developing major scientific
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2 Consistent with Caskey’s view, Science Watch ranked UTSW among the top ten universi-
ties in four of six categories of biomedical research in 2002 (Science Watch 2002).breakthroughs to better understand different diseases and to ultimately dis-
cover new treatments and methods of prevention. Looking ahead, the inter-
play between advances in biotechnology, informatics, and nanotechnology
could extend biotech applications to a wide array of products and services
inconceivable only a short time ago and greatly improve the quality of life
and bolster economic growth. But to succeed, biotech firms must draw on
specialists from different areas, foster technical collaboration among these
scientists and credibly communicate their findings to regulatory agencies,
customers, and investors.
The conference presentations also have implications for investors.
Direct implications include recognizing that there are high risks of having
large portfolio stakes in individual biotech firms, as reflected in the very
low success rate of biotech firms or new drugs (Darby and Zucker 2002;
Grabowski 2002; Howe 2002; and Zucker, Darby, and Armstrong 2002). In
addition, excluding pharmaceutical makers, biotech stock indexes had
very high valuations in April 2002, suggesting that this sector may have
been overvalued at the time of the conference.Given the difficulties in cap-
turing the value of inventions (Eisenberg 2002, Grabowski 2002, Howe
2002, and Lawlor 2002), investors should consider the risk that innova-
tions could benefit end users more than inventors.
Perhaps the biggest implications for investors arise from biotech’s
indirect effect on benefit costs and customer bases for all sorts of compa-
nies. In particular, biotech research could increase longevity beyond most
projections, a possibility Lichtenberg’s research suggests. As a result,
firms with large defined-benefit pension obligations could face greater
risks, as would the Social Security retirement system. The aging of the
population poses serious risks for medical expenses, as Howe empha-
sized. On the other hand, medical advances might help control the pro-
jected jump in Medicare benefits, which are expected to produce bigger
budget shortfalls than the looming Social Security problem (see Retten-
maier and Saving 1999).
In addition, spending patterns could shift by more than expected if
longevity increases more rapidly than projected, particularly if medical
advances reduce disabilities and improve the quality—as well as the
quantity—of life.
The conference presentations also had implications for local govern-
ment policies aimed at fostering biotech activity. The recipe for success in
biotech seems to be a strong scientific base built around top-rated aca-
demic institutions. These provide groundbreaking research and draw star
scientists to the region.The second important element is the ability to com-
mercialize the innovations coming out of the research institutions. To
become a major player in biotech, Texas needs to continue to develop its
strong research base but also needs increased venture capital to com-
mercialize innovations from the state’s research institutions.
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Glossary of Biotech Terms
Advanced Technology Program: Technology program instituted in 1990 by the
Department of Commerce to directly fund research into developing new generic
processes for high-tech industries.
Bioinformatics: The use of computers in solving information problems in the life 
sciences; mainly, it involves the creation of extensive electronic databases on
genomes, protein sequences, and so forth. Secondarily, it involves techniques
such as the three-dimensional modeling of biomolecules and biologic systems.
Biotechnology: “The use of microorganisms, such as bacteria or yeasts, or bio-
logical substances, such as enzymes, to perform specific industrial or manufac-
turing processes,” and more broadly, “the application of the principles of engineer-
ing and technology to the life sciences,” American Heritage Dictionary.
Clinical trials: The phase of research and development in which a product’s effec-
tiveness and safety are tested.
Cooperative Research and Development Agreement (CRADA): An agreement
under which federally funded laboratories establish profitable research links with
commercial firms that draw upon lab research findings.
Genomics: The scientific discipline that systematically investigates the set of chro-
mosomes and genes of an organism.
Gestation period: In the context of biotechnology, the period during which a 
product is being researched and developed, not including the development of prior
technologies used in the research.
Incremental progress: The type of technological progress in which an existing 
product is perfected or the process of making that product is perfected.
Inhibitor: A substance that suppresses or slows a chemical reaction.
Insulin: A hormone that regulates the metabolism of glucose, fats, and proteins.
Interferon: A protein that helps the body fight off viral infections.
Monoclonal antibody: An antibody that recognizes only one type of virus or 
bacterium.
Nanotechnology: The application of findings of nanoscale science, which deals
with objects as small as a nanometer (one billionth of a meter).
Nonclinical costs: The R&D costs incurred in addition to the costs of clinically
testing a product.
Proteomics: The use of quantitative protein-level measurements of how genes
behave and affect the body.
Recombinant DNA: A combination of DNA molecules of different origin that are
joined together using recombinant DNA techniques. Recombinant DNA is a frag-
ment of DNA incorporated artificially into the DNA molecule of a suitable vector 
so that it can express itself many times. This way, a large quantity of the DNA in
question can be obtained.
Stem cells: Cells that can develop into many different types of tissue and could
be the key to a number of therapeutic breakthroughs in the field of medicine and
research.
Venture capital: Private equity capital invested in a new or fresh enterprise.